Vericel击败了收入估计,并在强劲的季度结果和收入增长上提高份额。 Vericel beat earnings estimates and raised shares on strong quarterly results and revenue growth.

Vericel报告的季度收入比预期的更好,每股0.10美元,粗略估计为12美元,收入为6 750万美元,超过预测293万美元,逐年增加16.6%。 Vericel reported better-than-expected quarterly earnings, with $0.10 per share, beating estimates by $0.12, and $67.50 million in revenue, surpassing forecasts by $2.93 million, a 16.6% year-over-year increase. 生物制药公司推销运动医学和烧伤护理的细胞疗法,重申2025年全年指导,但没有具体细节。 The biopharmaceutical company, which markets cellular therapies for sports medicine and burn care, reaffirmed its full-year 2025 guidance without specifics. 重型贸易量的股份升至38.75美元。 Shares rose to $38.75 on heavy trading volume.